Retinal dystrophies : functional genomics to gene therapy
Author(s)
Bibliographic Information
Retinal dystrophies : functional genomics to gene therapy
(Novartis Foundation symposium, 255)
Wiley, 2004
Available at 3 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
" Novartis Foundation Symposium on Retinal dystrophies: functional genomics to gene therapy, held in collaboration with The Foundation Fighting Blindness at the Pier 5 Hotel, Baltimore, on 21-23 October 2002"
Includes bibliographical references and index
Description and Table of Contents
Description
Retinal dystrophies are the major causes of incurable blindness in the Western world. Our insight into their aetiology has improved remarkably over the past decade and a number of key genes have been identified. Together with a more detailed understanding of disease processes, this knowledge is stimulating new approaches to therapeutic strategies involving gene therapy, growth factors and retinal cell transplantation. Molecular genetic studies have provided detailed information on the pathogenesis of retinal dystrophies. An important proof of principle that gene therapy holds great promise for the treatment of these conditions was demonstrated in the rds mouse: introduction of a functional copy of the peripherin gene subretinally resulted in complete rescue of rod outer segment structure. Novel approaches are being developed based on the manipulation of biochemical pathways that previously were not considered relevant to these diseases. For example, renewed interest in retinal dystrophy pathogenesis led to the successful use of high dose vitamin A treatment in Sorsby fundus dystrophy.
This important new book covers all aspects of retinal dystrophies from the molecular and developmental biology of these disorders to possible therapeutic approaches, with special reference to gene therapy. Specific chapters deal with the molecular genetics of gene therapies, clinical genetic studies, molecular and cellular mechanisms of the development of the disease, functional genomics of retinal diseases, animal models of retinal dystrophies, and finally with studies on gene therapeutic approaches to correcting the disorder. With contributions by many of the leading researchers worldwide, this book is likely to be an important milestone in this rapidly developing field.
Table of Contents
Chair's Introduction (Shomi S Battacharya). Gene therapy of retinal dystrophies: Achievements, challenges and prospects (Dean Bok). Identifying retinal disease genes: how far have we come, how far do we have to go? (Stephen P Daiger). Dominant cone and cone-rod dystrophies: functional analysis of mutations in regGC1 and GCAP1 (David Hunt, Susan E Wilkie, Richard Newbold, Evelyne Deery, Martin J Warren, Shomi S Battacharya, and Kang Zhang). Isotretinoin treatment inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration (Roxana A Radu, Nathan L Mata, Steven Nusinowitz, Xinran Liu, and Gabriel H Travis). The expanding roles of ABCA4 and CRB1 in inherited blindness (F P M Cremers, A Maugeri, A I den Hollander, and C B Hoyng). What should a clinician know to be prepared for the advent of treatment of retinal dystrophies? (Alan C Bird). Role of subunit assembly in autosomal dominant retinitis pigmentosa link ed to mutations in perpherin 2 (Robert S Molday, Laurie L Molday, and Christopher J R Loewen). The search for rod-dependent cone viability factors, secretedd factors promoting cone viability (Thierry Leveillard, Saddek Mohand-Said, Anne-Claire Fintz, George Lambrou, and Jose-Alain Sahel). Studies on retinal and retinal pigment epithelial gene expression (Itay Chowers, Noriko Esumi, Peter Campochiaro, and Donald J Zack). From disease genes to cellular pathways: a progress report (J Yu, A J Mears, S Yoshida, R Farjo, T A Carter, D Ghosh, A Hero, C Barlow, and A Swaroop). Prospects for gene therapy (Robin R Ali). Range of retinal diseases potentially treatable by AAV-vectored gene therapy (William S Hauswirth, Quihong Li, Brian Raisler, Adrian M Timmers, Kenneth I Berns, John G Flannery, Matthew M LaVail, and Alfred S Lewin). Gene therapy for Leber congenital amaurosis (Jean Bennett). Index of Contributors. Subject Index.
by "Nielsen BookData"